- Poster presentation
- Open Access
A "prime-pull" immunotherapy approach using a lentiviral vector and intratumoral TLR4 agonist redirects cytotoxic T cells
© Albershardt et al.; licensee BioMed Central Ltd. 2014
- Published: 6 November 2014
- Tumor Bear Mouse
- TLR4 Agonist
- Intratumoral Injection
- Immune Effector Cell
- Tumor Challenge
The clinical efficacy of tumor specific effector T cells is limited by their proper trafficking to the site of the tumor and the locally immunosuppressive environment. Strategies to improve homing and activity of immune effector cells to tumors are needed to unlock the potential of active cancer immunotherapy.
B16F10-OVA melanoma bearing C57BL/6 mice were immunized with the lentiviral vector DCVex on 10 days after tumor challenge to induce OVA specific effector and memory CD8 T cells. Mice were then treated 12 days later intratumorally with the TLR4 agonist GLAAS (glucopyranosyl adjuvant system), which induces the T cell homing chemokines CXCL9 and CXCL10. Control mice received no treatment or only intratumoral GLAAS injection. Tumors were excised, homogenized, and the number and phenotype of OVA-specific infiltrating lymphocytes were analyzed via flow cytometry by staining cells with phenotyping cell surface markers and OVA-pentamers. Analysis was done 0, 24, and 48 hours after GLAAS injection.
Untreated, B16F10-OVA tumor bearing mice had no evidence of OVA specific CD4 or CD8 T cells by flow cytometry analysis. In contrast, a single injection with DCVex-OVA induced a peak response of 8-9% specific CD8 cells, which were detectable at low levels up to 35 days post-immunization. Intratumoral GLA administration of tumor bearing, DCVex immunized mice resulted in a mean of 7-fold intratumoral increase in OVA specific CD8 T cells, compared to mice treated with GLA only or left untreated.
Intratumoral injection of the TLR4 agonist GLAAS effectively redirects systemically induced CD8 T cells to the site of the tumor. Because GLAAS also stimulates antigen presentation and maturation of dendritic cells, the prime-pull approach may be a very effective way to overcome two major barriers to active cancer immunotherapy.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.